Omalizumab therapy could soon replace other, more toxic treatments
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
“Physicians and patients may now have a fast, safe and well-tolerated treatment option to consider before prescribing even more antihistamines, which can be highly sedating,” says Sarbjit (Romi) Saini, M.D., a Johns Hopkins allergist and immunologist, and study co-investigator. The research team’s findings are scheduled to be published in The New England Journal of Medicine online Feb. 24, to coincide with their initial presentation at the annual meeting of the American Academy of Allergy, Asthma & Immunology in San Antonio, Texas.
Participants in the study, which ran from 2009 to 2011, were mostly women and between the ages of 12 and 75. Each was randomly assigned to take one of three dosing regimens of omalizumab, or placebo, after which they were monitored through regular checkups for four months. Neither researchers nor participants were aware of what specific dose was being taken by which subjects during the study.
All study participants had chronic hives and rash for at least six months, with many having suffered from the condition for more than five years. All had continued to experience hives or a severe itchy rash for a full week while taking antihistamines.
“Patients suffering with this condition need more and better treatment options because chronic hives and rash are profoundly hard to treat and can be very debilitating,” says Saini, an associate professor at the Johns Hopkins University School of Medicine. Saini, who has studied omalizumab since 2005, points out that fewer than half of those treated respond to traditional drug treatments with antihistamines.
Saini says the new study results offer substantial evidence that this first injection treatment option not only works, but does so more safely than other drugs, such as corticosteroids and the immunosuppressant cyclosporine, which carry risk of potentially severe and toxic side effects, including high blood pressure, bone thinning and even infection. By contrast, headache was the most severe side effect observed with omalizumab therapy. No study participants died or suffered anaphylactic shock, or had to withdraw because of any adverse effects or events.
According to Saini, chronic idiopathic urticaria affects some 3 million Americans, and may or may not involve swelling, with twice as many women as men suffering from these often socially isolating conditions. Saini says some patients experience such severe swelling of their eyes, hands, face, lips and throat that they have difficulty breathing. Some refuse to leave home, losing several days at a time away from work during flare-ups.
In the study, the team of American and European researchers injected a 300-milligram dose of the drug, sold under the brand name Xolair, once a month for three months. Saini says initial relief from symptoms was quick and occurred after a week. After three months, 53 percent of people experienced a total elimination of all hives and 44 percent had no further incidents of hives or itch. Lower doses of the drug, at 150 milligrams and 75 milligrams, and the placebo (or 0 milligrams) proved half as effective as the next larger dose, or had almost no effect at all, researchers say.
The Latest Bing News on:
Treating chronic severe hives and itch
- What causes itchy skin? Doctors reveal the 9 common triggers - and when to worry about iton May 4, 2024 at 6:07 am
Itchy skin is a common problem with easy solutions, but you need to know what causes itchy skin before you can do something about it. Here, dermatologists reveal all ...
- The Challenging Diagnosis and Long Treatment Journey of CSU, From a Patient Perspectiveon May 3, 2024 at 12:16 pm
The pain of chronic spontaneous urticaria (CSU) can be crippling, explained Kristen Willard, a patient advocate with CSU, who discussed her treatment journey.
- Researchers are seeking people with chronic spontaneous urticaria for a studyon May 1, 2024 at 7:13 am
Individuals age 18 or older with symptomatic CSU are needed for a study at the Johns Hopkins Department of Allergy and Clinical Immunology ...
- I Have Chronic Allergies — and the Cure Is Almost As Bad As the Symptomson April 26, 2024 at 9:15 pm
TikTok star, Lauren Ramos, details her life with chronic allergies, including having to carry an epi-pen just to get allergy shots.
- Skin Problems & Treatments Resource Centeron April 26, 2024 at 9:01 am
Whether you're newly diagnosed with chronic spontaneous urticaria ... the sensation of itching, and their latest laboratory experiments point toward potentially effective treatments for people ...
- What are hives? A dermatologist explainson April 25, 2024 at 1:55 pm
Bug bites, sunlight and the heat of the season are just some of the triggers that could be causing your summertime hives.
- Stress Hives Can Be Itchy and Embarrassing — Here’s How To Speed Relief and Block Flare-Upson April 24, 2024 at 5:23 am
If you notice red, itchy welts suddenly popping up on your skin, you may start to panic. Are you having an allergic reaction? Did you catch something contagious? But your mystery rash may have a much ...
- Incyte to acquire San Diego pharma firm in $750 million dealon April 23, 2024 at 7:53 am
Incyte says the firm it is acquiring has new drug candidates representing multibillion-dollar revenue opportunities.
- Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidateson April 23, 2024 at 6:31 am
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market ...
- Chronic Spontaneous Urticaria: How do You Stop Treatment?on April 22, 2024 at 4:59 pm
A new study puts the spotlight on the lack of clarity in guidelines about when and how treatment of chronic spontaneous ... option for patients with severe urticaria refractory to antihistamines ...
The Latest Google Headlines on:
Treating chronic severe hives and itch
[google_news title=”” keyword=”treating chronic severe hives and itch” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]The Latest Bing News on:
Omalizumab
- Skin patch improves treatment for pediatric milk allergieson May 2, 2024 at 6:24 am
Daily immunotherapy delivered via a dermal patch reduced the risk of reactions, including anaphylaxis, in children with an immunoglobulin E (IgE)–mediated cow's milk allergy, according to a recent ...
- Chronic Spontaneous Urticaria: How do You Stop Treatment?on April 22, 2024 at 4:59 pm
However, in patients on high-dose antihistamines in combination with standard-dose omalizumab, 54% of physicians began weaning the antihistamine before the biologic. Fully 95% of physicians began ...
- Omalizumab: A Recombinant Humanized Anti-IgE Antibody for Allergic Asthmaon April 10, 2024 at 5:00 pm
Omalizumab is indicated for adults and adolescents (age 12 years or older) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial ...
- 10 mind-blowing facts about peanut allergies that every parent should knowon April 9, 2024 at 10:57 am
Palforzia is an FDA-approved drug for peanut allergy treatment, Maskatia pointed out, and the FDA also recently approved Xolair (omalizumab) for treating all food allergies, including peanut allergy.
- Dr. Roach: Immunotherapy for peanut allergies is still a work in progresson April 7, 2024 at 10:01 pm
A new treatment for food allergies was just approved by the Food and Drug Adminstration. Omalizumab works by blocking the immunoglobulin IgE, which is critically important in allergic diseases.
- Which Food Allergy Patients Will Benefit Most From Omalizumab?on April 7, 2024 at 5:00 pm
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Almost overnight, we've gone from having very few options ...
- 10 surprising facts about peanut allergies, according to a pediatric immunologiston April 7, 2024 at 2:30 am
Palforzia is an FDA-approved drug for peanut allergy treatment, Maskatia pointed out, and the FDA also recently approved Xolair (omalizumab) for treating all food allergies, including peanut allergy.
- Asthma Drug Xolair Now Indicated For Food Allergies: Next Challenge Is Insurer Coverageon March 5, 2024 at 12:54 pm
Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab) for immunoglobulin E-mediated food allergy in certain adults and children one year or older for the reduction of ...
- Asthma drug omalizumab may offer a safety net for those with multiple food allergies: studyon February 27, 2024 at 9:30 pm
A study published this week in the New England Journal of Medicine found the drug, called omalizumab, can reduce reactions to small amounts of allergens found in nuts, eggs, wheat and milk.
- What is Omalizumab? The asthma drug which study suggests could prevent allergic reactions to foodon February 27, 2024 at 4:43 am
Omalizumab has been shown to improve participants' responses to allergens The New England Journal of Medicine study could be a major breakthrough The FDA has approved the drug's use for the ...
The Latest Google Headlines on:
Omalizumab
[google_news title=”” keyword=”omalizumab” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]